The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Effect of iron chelation therapy on EPO-STAT5 signalling pathway and EPO resistance in iron-overloaded low-risk myelodysplastic syndrome patients
Open accessAbstract
Objectives: Background/aims: We aim to explore low-risk MDS patients’ ESA response and the difference between iron-overloaded (IO) group and the control group in the expression of SOCS1, STAT5 and BCL2L1 which play a key role to EPO-STAT5 signal pathway.Methods: 56 low-risk MDS patients were divided into experimental group, IO patients; control group, non-IO patients. Among experimental group, 28 IO patients were treated with iron chelation therapy (ICT). SOCS1, phosphorylated STAT5 (p-STAT5) and BCL2L1 protein concentration in bone marrow supernatant have been analyzed by ELISA, STAT5a+b protein concentration in bone marrow mononuclear cells (BMMC) have been analyzed by Western blot, and mRNA expression of them have been detected in BMMC by RQ-PCR. The percentage of CD71+ cells in BMMC, apoptotic rate of CD71+ cells and ROS expression in CD71+ cells were detected by Flow cytometry.Results: Compared with the control group, the sEPO concentration, the efficacy of ESA and the expression of SOCS1, apoptotic rates of CD71+ cells and ROS expression in CD71+ cells in IO group were increased, the expression of STAT5 and BCL2L1 was reduced. Interestingly, after receiving ICT, some patients with EPO resistance have responded again to ESA treatment, with the decrease of the expression of SOCS1, apoptotic rates of CD71+ cells, ROS expression in CD71+ cells and the increase of the expression of STAT5 and BCL2L1.Conclusion: Iron overload can increase EPO resistance and the expression of SOCS1, inhibit the expression of STAT5 and BCL2L1. ICT could allivation of EPO resistance.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Iron chelation appears to directly inhibit the expression of FoxP3, the master switch transcription factor of Tregs.”
From Iron in infection and immunity (2020) · cites this paper as Zhang, 2020
In the citing paper
“In addition, levels of CD25 and phosphorylation of STAT5 are reduced upon iron chelation (Bonaccorsi-Riani et al., 2015; Zhang, 2020; Zhang et al. , 2018a,b,c).”
From Iron in infection and immunity (2020) · cites this paper as Zhang, 2020
Citations
Cites
Vardiman, J. W., Thiele, J., Arber, D. A., Brunning, R. D., Borowitz, M. J., Porwit‐MacDonald, A., Harris, N. L., Beau, M. M. L., Hellström‐Lindberg, E., Tefferi, A., et al. (2009) · Blood · doi:10.1182/blood-2009-03-209262 · Cited by 4,532
Cheson, B. D. (2006) · Blood · doi:10.1182/blood-2005-10-4149 · Cited by 1,580
SOCS regulation of the JAK/STAT signalling pathway
Croker, B. A., Kiu, H., & Nicholson, S. E. (2008) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2008.07.010 · Cited by 639
IV. NKF-K/DOQI Clinical Practice Guidelines for Anemia of Chronic Kidney Disease: Update 2000
(2001) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(01)70008-x · Cited by 420
Hsieh, C.-C., & Papaconstantinou, J. (2006) · The FASEB Journal · doi:10.1096/fj.05-4376com · Cited by 205
Diwan, A., Koesters, A. G., Odley, A. M., Pushkaran, S., Baines, C. P., Spike, B. T., Daria, D., Jegga, A. G., Geiger, H., Aronow, B. J., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0610666104 · Cited by 161
Claessens, Y.-É., Bouscary, D., Dupont, J., Picard, F., Melle, J., Gisselbrecht, S., Lacombe, C., Dreyfus, F., Mayeux, P., & Fontenay, M. (2002) · Blood · doi:10.1182/blood.v99.5.1594 · Cited by 147
Stat5 activation enables erythropoiesis in the absence of EpoR and Jak2
Grebien, F., Kerenyi, M. A., Kovačic, B., Kolbe, T., Becker, V., Dolznig, H., Pfeffer, K., Klingmüller, U., Müller, M. M., Beug, H., et al. (2008) · Blood · doi:10.1182/blood-2007-07-102848 · Cited by 118
Zheng, Q., Zhao, Y., Guo, J., Zhao, S., Fei, C., Xiao, C. W., Wu, D., Wu, L., Li, X., & Chang, C. (2018) · Cell Death and Disease · doi:10.1038/s41419-018-0552-7 · Cited by 116
Saharinen, P., Ekman, N., Sarvas, K., Parker, P. J., Alitalo, K. K., & Silvennoinen, O. (1997) · Blood · doi:10.1182/blood.v90.11.4341 · Cited by 115
Research works printed but not linked: 5
- Zhang H, 2014, Chin J Hematol., 35, 18
- Zhang Y, 2014, J Exp Hematol, 22, 1027
- Hematology Branch of the Chinese Medical Association, 2012, Chin J Hematol, 33, 347
- Vardiman JW, Blood, 2009, 937
- 10.1007/s40620-014-0127-3 · DOI
Cited by
Iron in infection and immunity
Nairz, M., & Weiss, G. (2020) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2020.100864 · Cited by 359
STAT5 as a Key Protein of Erythropoietin Signalization
Tóthová, Z., Tomc, J., Debeljak, N., & Solár, P. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22137109 · Cited by 82
Iron metabolism in rheumatic diseases
Givian, A., Azizan, A., Jamshidi, A., Mahmoudi, M., & Farhadi, E. (2025) · Journal of Translational Autoimmunity · doi:10.1016/j.jtauto.2025.100267 · Cited by 10
Hemostatic therapy as a management strategy for acquired hemophilia: what does the future hold?
Franchini, M., Schiavulli, M., & Liumbruno, G. M. (2021) · Expert Review of Hematology · doi:10.1080/17474086.2021.1892483 · Cited by 7
Zhang, Y., Qian, Y., Song, L., Xiao, C. W., & Chang, C. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1058482 · Cited by 5
Self-citation
Metadata
- Authors
- Zhang, Y.
- Affiliations
- Shanghai Jiao Tong University (CN)
- Corresponding author
- Zhang, Yao
- ORCID
- Zhang, Yao
- Venue
- Hematology
- Publisher
- Informa UK Limited
- Published
- 2019-12-15
- Volume
- 25
- Issue
- 1
- Pages
- 1-10
- ISSN
- 1024-5332 (ISSN-L)
- 1607-8454
- OpenAlex
- W2994785145
- Cited by
- 9
- References
- 28
- Citations by year
- 2025: 2 · 2024: 2 · 2022: 1 · 2021: 3 · 2020: 1
- FWCI
- 0.89
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- Hematology (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Hematology › Erythropoietin and Anemia Treatment
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Health Sciences › Medicine › Hematology › Iron Metabolism and Disorders
- Keywords
- iron chelation therapy, myelodysplastic syndrome, low-risk MDS, iron overload, erythropoietin resistance, SOCS1, STAT5, Bcl-xL, erythropoiesis-stimulating agents, apoptosis, reactive oxygen species, bone marrow mononuclear cells
- MeSH terms
- Adult, Aged, Aged, 80 and over, Erythropoietin, Female, Hematinics, Humans, Iron Chelating Agents, Male, Middle Aged, Myelodysplastic Syndromes, Signal Transduction, Chelation Therapy, Iron Overload, Tumor Suppressor Proteins, STAT5 Transcription Factor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effect of iron chelation therapy on EPO-STAT5 signalling pathway and EPO resistance in iron-overloaded low-risk myelodysplastic syndrome patients. https://app.cochat.ai/papers/10.1080/16078454.2019.1700330
- The paper
- Zhang, Y. (2020). Effect of iron chelation therapy on EPO-STAT5 signalling pathway and EPO resistance in iron-overloaded low-risk myelodysplastic syndrome patients. Hematology. https://doi.org/10.1080/16078454.2019.1700330
